LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article ; Online: Pulmonary Embolism at CT Pulmonary Angiography in Patients with COVID-19.

Kaminetzky, Mark / Moore, William / Fansiwala, Kush / Babb, James S / Kaminetzky, David / Horwitz, Leora I / McGuinness, Georgeann / Knoll, Abraham / Ko, Jane P

Radiology. Cardiothoracic imaging

2020 Volume 2, Issue 4, Page(s) e200308

Abstract: Purpose: To evaluate pulmonary embolism (PE) prevalence at CT pulmonary angiography in patients testing positive for coronavirus disease 2019 (COVID-19) and factors associated with PE severity.: Materials and methods: A retrospective, single-center ... ...

Abstract	Purpose: To evaluate pulmonary embolism (PE) prevalence at CT pulmonary angiography in patients testing positive for coronavirus disease 2019 (COVID-19) and factors associated with PE severity. Materials and methods: A retrospective, single-center study evaluated 62 patients who tested positive for COVID-19 who underwent CT pulmonary angiography between March 13 and April 5, 2020. Another 62-patient cohort who underwent CT pulmonary angiography before the first reported local COVID-19 case was retrospectively selected. The relative rate of CT pulmonary angiography positivity was recorded. For the COVID-19 positive cohort, comorbidities, laboratory values, clinical outcome, and venous thrombosis of the patients were recorded. Two thoracic radiologists assessed embolic severity using the Mastora system and evaluated right heart strain. Factors associated with PE and arterial obstruction severity were evaluated by using statistical analysis. A Results: Of the patients testing positive for COVID-19, 37.1% had PE, higher than 14.5% of pre-COVID-19 patients ( Conclusion: A total of 37.1% of COVID-19 patients underwent CT pulmonary angiographic examinations diagnosing PE. PE can be a cause of decompensation in patients testing positive for COVID-19, and d-dimer can be used to stratify patients in terms of PE risk and severity.
Language	English
Publishing date	2020-07-02
Publishing country	United States
Document type	Journal Article
ISSN	2638-6135
ISSN (online)	2638-6135
DOI	10.1148/ryct.2020200308
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Pulmonary Embolism on CTPA in COVID-19 Patients

Kaminetzky, Mark / Moore, William / Fansiwala, Kush / Babb, James S. / Kaminetzky, David / Horwitz, Leora I. / McGuinness, Georgeann / Knoll, Abraham / Ko, Jane P.

Radiol Cardiothorac Imaging

Abstract: BACKGROUND: Understanding pulmonary embolism (PE) rate and contributing comorbid, clinical, laboratory, and imaging characteristics may aid in management of pro-thombotic events in COVID-19 (COVID+) patients. PURPOSE: To evaluate PE prevalence on ... ...

Abstract	BACKGROUND: Understanding pulmonary embolism (PE) rate and contributing comorbid, clinical, laboratory, and imaging characteristics may aid in management of pro-thombotic events in COVID-19 (COVID+) patients. PURPOSE: To evaluate PE prevalence on computed tomography pulmonary angiogram (CTPA) in COVID+ patients and factors associated with PE severity. MATERIALS AND METHODS: A retrospective, single-center study evaluated 62 COVID+ patients who underwent CTPA between March 13 and April 5, 2020. A 62-patient cohort who underwent CTPA prior to the first reported local COVID-19 case was retrogradely selected. The relative rate of CTPA-positivity was recorded. For the COVID+ cohort, comorbidities, laboratory values, clinical outcome, and venous thrombosis were recorded. Two thoracic radiologists assessed embolic severity using the Mastora system and evaluated right heart strain. Statistical analysis evaluated factors associated with PE and arterial obstruction severity. A P-value<.05 was considered significant. RESULTS: 37.1% of COVID+ patients had PE, higher than 14.5% of pre-COVID patients (P=.007). D-dimer levels closest to CTPA date correlated with Mastora obstruction score. ROC analysis identified optimal sensitivity (95%) and specificity (71%) for PE diagnosis at 1394 ng/mL DDU. The mean D-dimer was 1774 ng/mL and 6432 ng/mL DDU in CTPA-negative and CTPA-positive subgroups, respectively (P<.001). One additional CTPA-negative patient had DVT, for a total 38.7% with PE/DVT, despite 40% receiving prophylactic anticoagulation. Other factors did not demonstrate significant PE association. CONCLUSION: 37.1% of COVID+ CTPA exams diagnosed PE. PE can be a cause of decompensation in COVID+, and D-dimer can be used to stratify patients regarding PE risk and severity.
Keywords	covid19
Publisher	PMC
Document type	Article ; Online
DOI	10.1148/ryct.2020200308
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Effectiveness of Lung-RADS in Reducing False-Positive Results in a Diverse, Underserved, Urban Lung Cancer Screening Cohort.

Kaminetzky, Mark / Milch, Hannah S / Shmukler, Anna / Kessler, Abraham / Peng, Robert / Mardakhaev, Edward / Bellin, Eran Y / Levsky, Jeffrey M / Haramati, Linda B

Journal of the American College of Radiology : JACR

2018 Volume 16, Issue 4 Pt A, Page(s) 419–426

Abstract: Purpose: The Lung CT Screening Reporting and Data System: Methods: Institutional review board approval was obtained to study the clinical lung cancer screening cohort. Low-dose CT results were prospectively assigned a Lung-RADS or equivalent score. ... ...

Abstract	Purpose: The Lung CT Screening Reporting and Data System Methods: Institutional review board approval was obtained to study the clinical lung cancer screening cohort. Low-dose CT results were prospectively assigned a Lung-RADS or equivalent score. The proportion of examinations in each Lung-RADS category and the corresponding lung cancer rate, subsequent imaging, interventions, mortality, and compliance were tracked. The National Death Index was queried for follow-up losses. Results: The cohort comprised 1,181 patients with 2,270 person-years of follow-up from December 2012 to December 2016. The mean age was 64 ± 16.2 years, with 51% women, 63% nonwhite, 71% current smokers, 69% overweight and obese, and multiple comorbidities. The Lung-RADS false-positive rate was 10.4% (95% confidence interval, 8.8%-12.3%). Baseline CT results were negative in 87% (n = 1,031): for Lung-RADS 1, the lung cancer rate was 0.2%, and for Lung-RADS 2, the cancer rate was 0.5%. Positive baseline examinations were Lung-RADS 3 in 10% (n = 119), 4a in 1.2% (n = 14), and 4b in 1.5% (n = 18). Corresponding cancer rates were 3.4%, 43%, and 83%, respectively. Lung cancer prevalence was 2.1%. Mortality was 40% in patients with lung cancer versus 2.5% in the remaining cohort (P < .001). Fifty-four percent of patients were overdue for first annual examinations. Eighty-four percent of patients (n = 989) had follow-up verified via electronic records or personal contact, and the remainder had vital status ascertained via the National Death Index. Conclusions: Lung cancer screening using Lung-RADS was effective in reducing the false-positive rate compared with the National Lung Screening Trial in a diverse and underserved urban population.
MeSH term(s)	Aged ; False Positive Reactions ; Female ; Humans ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/epidemiology ; Lung Neoplasms/mortality ; Male ; Mass Screening/methods ; Middle Aged ; New York City/epidemiology ; Prevalence ; Prospective Studies ; Tomography, X-Ray Computed ; Urban Population
Language	English
Publishing date	2018-08-23
Publishing country	United States
Document type	Journal Article
ZDB-ID	2274861-1
ISSN	1558-349X ; 1546-1440
ISSN (online)	1558-349X
ISSN	1546-1440
DOI	10.1016/j.jacr.2018.07.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6636: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients.

Caro, Jessica / Braunstein, Marc / Williams, Louis / Bruno, Benedetto / Kaminetzky, David / Siegel, Ariel / Razzo, Beatrice / Alfandari, Serge / Morgan, Gareth J / Davies, Faith E / Boyle, Eileen M

Leukemia

2022 Volume 36, Issue 3, Page(s) 613–624

Abstract: The role of infection and chronic inflammation in plasma cell disorders (PCD) has been well-described. Despite not being a diagnostic criterion, infection is a common complication of most PCD and represents a significant cause of morbidity and mortality ... ...

Abstract	The role of infection and chronic inflammation in plasma cell disorders (PCD) has been well-described. Despite not being a diagnostic criterion, infection is a common complication of most PCD and represents a significant cause of morbidity and mortality in this population. As immune-based therapeutic agents are being increasingly used in multiple myeloma, it is important to recognize their impact on the epidemiology of infections and to identify preventive measures to improve outcomes. This review outlines the multiple factors attributed to the high infectious risk in PCD (e.g. the underlying disease status, patient age and comorbidities, and myeloma-directed treatment), with the aim of highlighting future prophylactic and preventive strategies that could be implemented in the clinic. Beyond this, infection and pathogens as an entity are believed to also influence disease biology from initiation to response to treatment and progression through a complex interplay involving pathogen exposure, chronic inflammation, and immune response. This review will outline both the direct and indirect role played by oncogenic pathogens in PCD, highlight the requirement for large-scale studies to decipher the precise implication of the microbiome and direct pathogens in the natural history of myeloma and its precursor disease states, and understand how, in turn, pathogens shape plasma cell biology.
MeSH term(s)	Adaptive Immunity ; Animals ; Humans ; Immunity, Innate ; Infections/complications ; Infections/immunology ; Infections/pathology ; Inflammation/complications ; Inflammation/immunology ; Inflammation/pathology ; Multiple Myeloma/etiology ; Multiple Myeloma/immunology ; Multiple Myeloma/pathology ; Plasma Cells/immunology ; Plasma Cells/pathology
Language	English
Publishing date	2022-02-02
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	807030-1
ISSN	1476-5551 ; 0887-6924
ISSN (online)	1476-5551
ISSN	0887-6924
DOI	10.1038/s41375-021-01506-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2295: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.

Chughtai, Bilal / Elterman, Dean / Shore, Neal / Gittleman, Marc / Motola, Jay / Pike, Sheldon / Hermann, Craig / Terrens, William / Kohan, Alfred / Gonzalez, Ricardo R / Katz, Aaron / Schiff, Jeffery / Goldfischer, Evan / Grunberger, Ivan / Tu, Le Mai / Alshak, Mark N / Kaminetzky, Jed

Urology

2020 Volume 153, Page(s) 270–276

Abstract: Objective: To report the results of a multicenter, randomized, controlled trial with a temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Hadera, Israel) compared to sham for the treatment of lower urinary tract symptoms secondary to benign ... ...

Abstract	Objective: To report the results of a multicenter, randomized, controlled trial with a temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Hadera, Israel) compared to sham for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and methods: Men 50 years or older were randomized 2:1 between iTind and sham procedure arms. A self-expanding, temporary nitinol device was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, respectively. Patients were assessed at baseline, 1.5, 3, and 12 months postoperatively using the IPSS, peak urinary flow rate, residual urine, quality of life, and the International Index of Erectile Function. Unblinding occurred at 3 months. Results: A total of 175 men (mean age 61.1 ± 6.5) participated (118 iTind vs 57 sham). A total of 78.6% of patients in the iTind arm showed a reduction of ≥3 points in IPSS, vs 60% of patients in the control arm at 3 months. At 12 months, the iTind group reported a 9.25 decrease in IPSS (P< .0001), a 3.52ml/s increase in peak urinary flow rate (P < .0001) and a 1.9-point reduction in quality of life (P < .0001). Adverse events were typically mild and transient, most Clavien-Dindo grade I or II, in 38.1% of patients in the iTind arm and 17.5% in the control arm. No de novo ejaculatory or erectile dysfunction occurred. Conclusion: Treatment with the second-generation iTind provided rapid and sustained improvement in lower urinary tract symptoms for the study period while preserving sexual function.
MeSH term(s)	Alloys ; Humans ; Lower Urinary Tract Symptoms/etiology ; Lower Urinary Tract Symptoms/surgery ; Male ; Middle Aged ; Prospective Studies ; Prostatic Hyperplasia/complications ; Prostheses and Implants ; Single-Blind Method
Chemical Substances	Alloys ; nitinol (2EWL73IJ7F)
Language	English
Publishing date	2020-12-26
Publishing country	United States
Document type	Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	192062-5
ISSN	1527-9995 ; 0090-4295
ISSN (online)	1527-9995
ISSN	0090-4295
DOI	10.1016/j.urology.2020.12.022
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1142: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 275: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Computed tomography screening for lung cancer: preliminary results in a diverse urban population.

Milch, Hannah / Kaminetzky, Mark / Pak, Pamela / Godelman, Alla / Shmukler, Anna / Koenigsberg, Tova C / Haramati, Linda B

Journal of thoracic imaging

2015 Volume 30, Issue 2, Page(s) 157–163

Abstract: Purpose: The purpose of this study was to describe the baseline characteristics and results of the initial 18 months of our clinical computed tomography (CT) lung cancer screening program in an ethnically diverse, poor, predominantly overweight, and ... ...

Abstract	Purpose: The purpose of this study was to describe the baseline characteristics and results of the initial 18 months of our clinical computed tomography (CT) lung cancer screening program in an ethnically diverse, poor, predominantly overweight, and obese population, which differs dramatically from the National Lung Screening Trial population. Materials and methods: All patients had a physician referral for CT lung cancer screening and met National Lung Screening Trial eligibility criteria. Infrastructure developed for the program included a standardized results report [Bronx score of 1 to 5 (modeled on BI-RADS)] for the electronic medical record and a dedicated bilingual screening coordinator. If the patient's insurance did not cover CT screening, a fee of $75 was charged. Results: A total of 320 patients [54% (174) men, mean age 64 y] underwent initial CT lung cancer screening from December 18, 2012 to July 3, 2014. The median pack-years was 47, and 68% (218) were current smokers. Twenty-six percent (84) were white, and 70% (223) were overweight (101) or obese (122). The lung cancer prevalence was 2.2% (7/320). Seventy-eight percent (7/9) of patients with CT findings positive for lung cancer (score 5a, 5b) had proven lung cancer; 1 had stage 1 (1B) disease, and 6 had stage IIA or higher disease. The false-positive rate for a Bronx score ≥3 was 19% (60). Medicare and Medicaid insure 80% of the institution's overall population but only 38% (121) of the CT screening patients. Conclusions: CT screening is feasible in a diverse inner-city population with the support of a robust infrastructure. Further study is needed to determine whether CT screening will confer a mortality benefit in this population.
MeSH term(s)	Early Detection of Cancer/methods ; Humans ; Lung Neoplasms/diagnostic imaging ; Mass Screening/methods ; Tomography, X-Ray Computed ; Urban Population
Language	English
Publishing date	2015-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	632900-7
ISSN	1536-0237 ; 0883-5993
ISSN (online)	1536-0237
ISSN	0883-5993
DOI	10.1097/RTI.0000000000000123
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2187: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chromothripsis as a pathogenic driver of multiple myeloma.

Maura, Francesco / Boyle, Eileen M / Rustad, Even H / Ashby, Cody / Kaminetzky, David / Bruno, Benedetto / Braunstein, Marc / Bauer, Michael / Blaney, Patrick / Wang, Yubao / Ghamlouch, Hussein / Williams, Louis / Stoeckle, James / Davies, Faith E / Walker, Brian A / Maclachlan, Kylee / Diamond, Ben / Landgren, Ola / Morgan, Gareth J

Seminars in cell & developmental biology

2021 Volume 123, Page(s) 115–123

Abstract: Analysis of the genetic basis for multiple myeloma (MM) has informed many of our current concepts of the biology that underlies disease initiation and progression. Studying these events in further detail is predicted to deliver important insights into ... ...

Abstract	Analysis of the genetic basis for multiple myeloma (MM) has informed many of our current concepts of the biology that underlies disease initiation and progression. Studying these events in further detail is predicted to deliver important insights into its pathogenesis, prognosis and treatment. Information from whole genome sequencing of structural variation is revealing the role of these events as drivers of MM. In particular, we discuss how the insights we have gained from studying chromothripsis suggest that it can be used to provide information on disease initiation and that, as a consequence, it can be used for the clinical classification of myeloma precursor diseases allowing for early intervention and prognostic determination. For newly diagnosed MM, the integration of information on the presence of chromothripsis has the potential to significantly enhance current risk prediction strategies and to better characterize patients with high-risk disease biology. In this article we summarize the genetic basis for MM and the role played by chromothripsis as a critical pathogenic factor active at early disease phases.
MeSH term(s)	Chromothripsis ; Humans ; Multiple Myeloma/diagnosis ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Whole Genome Sequencing
Language	English
Publishing date	2021-05-03
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1312473-0
ISSN	1096-3634 ; 1084-9521
ISSN (online)	1096-3634
ISSN	1084-9521
DOI	10.1016/j.semcdb.2021.04.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2918: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length.

Boyle, Eileen M / Williams, Louis / Blaney, Patrick / Ashby, Cody / Bauer, Michael / Walker, Brian A / Ghamlouch, Hussein / Choi, Jinyoung / Perrial, Emeline / Wang, Yubao / Caro, Jessica / Stoeckle, James H / Arbini, Arnaldo / Kaminetzky, David / Braunstein, Marc / Bruno, Benedetto / Razzo, Beatrice / Diamond, Benjamin / Maclachlan, Kylee /

Maura, Francesco / Landgren, Ola / Litke, Rachel / Fegan, Christopher D / Keats, Johnathan / Auclair, Daniel / Davies, Faith E / Morgan, Gareth J

Leukemia

2021 Volume 36, Issue 1, Page(s) 221–224

MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Clonal Hematopoiesis ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Multiple Myeloma/therapy ; Prognosis ; RNA-Seq ; Survival Rate ; Telomere Homeostasis
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2021-06-19
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	807030-1
ISSN	1476-5551 ; 0887-6924
ISSN (online)	1476-5551
ISSN	0887-6924
DOI	10.1038/s41375-021-01320-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2295: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

Hultcrantz, Malin / Richter, Joshua / Rosenbaum, Cara A / Patel, Dhwani / Smith, Eric L / Korde, Neha / Lu, Sydney X / Mailankody, Sham / Shah, Urvi A / Lesokhin, Alexander M / Hassoun, Hani / Tan, Carlyn / Maura, Francesco / Derkach, Andriy / Diamond, Benjamin / Rossi, Adriana / Pearse, Roger / Madduri, Deepu / Chari, Ajai /

Kaminetzky, David / Braunstein, Marc J / Gordillo, Christian / Reshef, Ran / Taur, Ying / Davies, Faith E / Jagannath, Sundar / Niesvizky, Ruben / Lentzsch, Suzanne / Morgan, Gareth J / Landgren, Ola

Blood cancer discovery

2020 Volume 1, Issue 3, Page(s) 290

Abstract: This corrects the article DOI: 10.1158/2643-3230.BCD-20-0102.]. ...

Abstract	[This corrects the article DOI: 10.1158/2643-3230.BCD-20-0102.].
Language	English
Publishing date	2020-11-04
Publishing country	United States
Document type	Journal Article ; Published Erratum
ZDB-ID	3028898-8
ISSN	2643-3249 ; 2643-3230
ISSN (online)	2643-3249
ISSN	2643-3230
DOI	10.1158/2643-3230.BCD-20-0160
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

Kaminetzky, David / Braunstein, Marc J / Gordillo, Christian / Reshef, Ran / Taur, Ying / Davies, Faith E / Jagannath, Sundar / Niesvizky, Ruben / Lentzsch, Suzanne / Morgan, Gareth J / Landgren, Ola

Blood cancer discovery

2020 Volume 1, Issue 3, Page(s) 234–243

Abstract: Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID-19. Here, we report outcomes and risk factors for serious disease in patients with ... ...

Abstract	Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID-19. Here, we report outcomes and risk factors for serious disease in patients with multiple myeloma treated at five large academic centers in New York City in the spring of 2020, during which it was a global epicenter of the SARS-CoV-2 pandemic. Of 100 patients with multiple myeloma (male 58%; median age 68) diagnosed with COVID-19, 75 were admitted; of these, 13 patients (17%) were placed on invasive mechanical ventilation, and 22 patients (29%) expired. Of the 25 nonadmitted patients, 4 were asymptomatic. There was a higher risk of adverse outcome (intensive care unit admission, mechanical ventilation, or death) in Hispanics/Latinos ( Significance: Patients with multiple myeloma are immunocompromised, raising the question whether they are at higher risk of severe COVID-19 disease. In this large case series on COVID-19 in patients with multiple myeloma, we report 29% mortality rates among hospitalized patients and identify race/ethnicity as the most significant risk factor for severe outcome.
Language	English
Publishing date	2020-07-30
Publishing country	United States
Document type	Journal Article
ZDB-ID	3028898-8
ISSN	2643-3249 ; 2643-3230
ISSN (online)	2643-3249
ISSN	2643-3230
DOI	10.1158/2643-3230.BCD-20-0102
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito